基因多态性对氟伐他汀药代动力学和药效学特征的影响

摘要/Abstract

摘要： 氟伐他汀是第一个全化学合成的降胆固醇药物,在临床治疗应用中存在较大的个体疗效差异。肌毒性、肝毒性,横纹肌溶解等是氟伐他汀的潜在不良反应。为了降低不良反应的发生率,研究导致氟伐他汀个体差异大的原因具有重大意义。本文综述了CYP450酶、药物转运体(OATP1B1、OATP1B3、OATP2B1、ABCG2) 多态性对氟伐他汀药代动力学特征的影响和药效基因(CETP、ApoE)的多态性对氟伐他汀药效学特征的影响。以期确保临床用药的安全性和有效性,真正实现临床上的个体化给药。

关键词: 氟伐他汀, 药代动力学特征, 药效学特征, 基因多态性

Abstract: Fluvastatin is the first all chemical synthesis of cholesterol drugs. In the clinical treatment of the application of existing large differences.Muscle toxicity, liver toxicity,rhabdomyolysis is fluvastatin potential adverse reactions. In order to reduce the incidence of adverse reactions, so the lead to fluvastatin individual differences of the big reason has the great significance. This paper reviewes the CYP450 enzyme, drug transport body (OATP1B1, OATP1B3, OATP2B1, ABCG2) to fluvastatin pharmacokinetics characteristics of the influence and pharmacophore (CETP, ApoE) to fluoride polymorphisms of simvastatin pharmacodynamics characteristics influence. So as to ensure that the safety and efficacy of clinical medicine, and achieved the clinical personalized medicine.

Key words: Fluvastatin, Pharmacokinetics characteristics, Pharmacodynamics characteristics, Gene polymorphism

中图分类号:

R969

刘婧, 熊玉卿. 基因多态性对氟伐他汀药代动力学和药效学特征的影响[J]. 中国临床药理学与治疗学, 2012, 17(11): 1282-1288.

LIU Jing, XIONG Yu-qing. Influence of related genetic polymorphisms to pharmacokinetics and pharmacodynamics of Fluvastatin[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(11): 1282-1288.

参考文献

[1] Evans WE,Relling MV.Pharmacogenomics: translating functional genomics into rational therapeutics[J]. Science, 1999, 286(5439): 487-491.
[2] 章飞凤. 氟伐他汀的研究进展[J].中国实用医药, 2007, 2(34):139-141.
[3] Kopplow K, Letsch ERT K, Konjg J, et al.Human heap-tobiliary transport of organic anions analyzed by quadruple-transfected cells[J]. MolPhamacol, 2005, 68(4):1031-1038.
[4] Charity D Scripture, John A Pieper.Clinical pharmacokinetics of fluvastatin[J].Clin pharmacokinet, 2001, 40(4): 263-281.
[5] Volker Fischer, Laurie Johanson, Francis Heitz, et al.The 3-hydroxy-3-methylglutaryl coenzy mea reductase inhibitor fluvastatin: effect on human cytochrome p-450 and implications for metabolic drug interactions[J]. Drug Metab Dispos, 1998, 27(3): 410-415.
[6] Toda T, Eliasson E, Ask B, et al.Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes[J]. Basic Clin Pharmacol Toxicol, 2009, 105(5): 327-332.
[7] Blum CB.Comparison of properties of four inhibitors of 3-hydroxy-3- methylglutaryl-coenzyme A reductase[J]. Am J Cardiol,1994, 73(14): 3D-11D.
[8] 杨永革, 王占庆, 姜喃,等.他汀类药物的不良反应[J].医药导报, 2011, 30(6) : 817-820.
[9] Hagen E, Lstak H, Oae L, et al.Detachment and cytolysis of human endothelial cell by proteinase3[J]. Eur J Clinpharmaco, 1994, 24(12): 3211-3215.
[10] Niemi M, Backman JT, Kajosaari LI, et al.Polymorphic organicanion transporting polypept de 1B1 is a major determinant of repaglinide pharmacokinetics[J]. Clin Pharmacol Ther, 2005, 77(6): 468-478.
[11] Tirona RG, Leake BF, Merino G, et al.Polymorphic in OATP-C; identification of multiple alleic Variants associated with altered transport activity among European- and Africa n-America- ns[J]. J Biol Chem, 2001, 276(38): 35669-35675.
[12] Nozawa T, Nakajima M, Tamai I, et al.Genetic polymorphisms of human organicanion tran-sporters oatp-c and oatp-b; allele frequencies in the japanese population and functional analysis[J]. Phatmacol Exp Ther, 2002, 302(2): 804-813.
[13] Nishizato Y, Ieier I, Suzuki H, et al.Polymorphisms of OATP-C and OATP3 genes; consepuences for pravastatin pharmacokinetics[J]. Chin pharmacol Ther, 2003, 73(6): 554-565.
[14] Johannes Noe’, Rene’e Portmann, Marie-Elise Brun, et al.Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP)Substrates on OATP1B1, OATP2B1, and OATP1B3[J].The American Society for Pharmacology and Experimental Therapeutics, 2007, 35(8): 1308-1314.
[15] Philippe C, Philippe G, Sylvie D, et al.Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy[J]. Pharmacogenomics, 2008, 9(9): 1217-1227.
[16] Deng JW, Song IS, Shin HJ, et al.The effect of SLCO1B1*15 on the disposition of pravastatin is substrate; the contribution of transporting activity changes by SLCO1B1 *15[J]. Pharm dependent acogener Genomics, 2008, 18(5):424-433.
[17] 陈騉, 王睿. 药物代谢酶细胞色素P4502C9研究进展[J].中国临床药理学与治疗学, 2004, 9(6): 601-606.
[18] Niemi M, Cascorbi I, Timm R, et al.Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes[J]. Clin Pharmacol Ther, 2002, 72(3): 326-332.
[19] Kirchheiner J, Kudlicz D, Meisel C, et al.Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S, 5R-fluvastatin and (+)-3R, 5S-fluvastatin in healthy volunteers[J]. Clin Pharmacol Ther, 2003, 74(2): 186-194.
[20] Elizabeta Topic, Mario Sˇ tefanovic, et al. Association between the CYP2C9 polymorphism and the drug metabolism phenotype[J]. Clin Chem Lab Med, 2004, 42(1): 72-78.
[21] Min Kim, Turnquist H, Jackson J, et al.The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is over expressed in hematopoietic stem cells[J]. Clin Can Res, 2002, 8(1): 22-28.
[22] Keskitalo JE, Pasanen MK, Neuvomen PJ, et al.Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin[J]. Phar pharmaco genomics, 2009, 10(10): 1617-1624.
[23] Maitland-Vander zee AH, Klungel OH, Stricker BH, et al. Genetic Polymorphisms importance for response to HMG-COA reductase inhibitors[J]. Atherosclerosi, 2002, 163(2): 213-222.
[24] Agellon L, Quinet E, Gilletle D, et al.Organization of the human cholestery esten transrerproein gene[J] . Biochemistry, 1990, 29(6): 1372-1376.
[25] Nagano M, Yamashita S, Hirano K, et al.Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese[J]. J Atherosclen Thromb, 2004, 11(3): 110-121.
[26] Hong SH, Kim YR, Song J, Kim JQ, et al.Genetic variations of cholesterol ester transfer prot- ein gene in Koreans[J]. Hum Biol, 2001, 73(6): 815-821.
[27] 朱燕林, 严晓伟, 鄢盛凯,等.胆固醇酯转移蛋白TaqB基因多态性与辛伐他汀调脂疗效的相关性[J] .中国临床药理学杂志, 2004, 152(3): 367-375.
[28] 张震宇, 王颍, 谢玉才,等. 胆固醇酯转移蛋白与氟伐他汀降脂疗效的关系[J].临床心血管杂志, 2008, 24(8): 590-592.
[29] Yamashita S, Hiranok Sakain.Molecular biology and patho physiological aspecs of plasma cholesterol ester transfer protein[J]. Biochin Biophys Acta, 2000, 1529(1/2/3): 257-275.
[30] Ballantyne CM, Herd JA, Stenea, et al. The apolipoprotein4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infatction:a substudy of the Scandinavian simvastatin survual study[J]. Circulation,2000, 101(12): 1366-1371.
[31] 周权, 阮邹荣, 袁虹,等. 反相高效液相色谱法测定人血浆中氟伐他汀浓度及其药动学研究应用[J] .中国药学杂志, 2006, 41(12): 1651-1653.